This biotechnology company develops xeno-free ancillary products for rapid T-cell expansion and activation ex vivo, alongside recombinant protein signals for cell therapeutic research. Their offerings aim to simplify and accelerate the development of cell therapeutic products.
Funding
Funding not disclosed
Founders
Product
Problem
Current methods for ex vivo T-cell expansion and activation often involve animal-derived components and complex procedures, leading to variability, safety concerns, and increased development time for cell therapies. Traditional methods may also result in T-cell exhaustion and reduced therapeutic efficacy.
Solution
Allegrow Biotech develops xeno-free ancillary products based on their AimGel artificial cell technology to streamline and enhance ex vivo immune cell expansion and activation. AimGel mimics the immunological synapse by presenting signals on a fluid membrane, resulting in more efficient and higher quality cell expansion in a shorter timeframe. The hydrogel-based artificial cells degrade naturally via hydrolysis after expansion, eliminating the need for cumbersome debeading steps. Allegrow's products offer a chemically defined, animal-free system for generating robust and functional immune cells for cell therapy research and development.
Target Audience
The primary target audience includes researchers and companies involved in cell therapy development, particularly those focused on T-cell, NK-cell, and Treg-based therapies, as well as clinical researchers seeking to improve immune cell expansion protocols.
Features
- AimGel artificial cells that mimic the immunological synapse for enhanced cell-cell interaction
- Xeno-free and chemically defined composition, reducing variability and safety concerns
- Hydrogel-based microparticles that self-degrade via hydrolysis, eliminating the need for debeading
- AimTconv product for expansion of conventional T cells with less exhaustion and more memory subtypes, utilizing CD3/CD28 activation signals
- AimNK product for feeder-cell free expansion of natural killer cells
- AimTreg product for expansion and activation of regulatory T cells
- Demonstrated 5.7X greater expansion of NK cells compared to conventional methods
- Protocols and resources available for AimTconv to guide T cell expansion and activation